SPECT/CT for the Characterization of Renal Masses

Launched by JONSSON COMPREHENSIVE CANCER CENTER · Jun 21, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at a special imaging test called technetium Tc-99m sestamibi SPECT/CT to see how well it helps doctors make decisions about treating patients with kidney tumors. The goal is to find out if this test can provide important information about kidney masses in a way that is less invasive than traditional methods. If you or a loved one has been diagnosed with a kidney tumor recently and is considering treatment options, this study might be a good fit.

To be eligible for this trial, participants should be generally healthy with a life expectancy of over a year, and they must have a solid kidney tumor that is between 1.5 and 5.0 centimeters in size. It’s important that the tumors are new (diagnosed within the last three months) and that there is no evidence of cancer spreading to other parts of the body. Participants will undergo the imaging test and will have the chance to receive more information to help them and their doctors make informed decisions about treatment. If you're interested, it's essential to be willing to answer questions and provide consent to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Performance status Eastern Cooperative Oncology Group (ECOG) \< 2.
• • Life expectancy (\> 1 year).
• • New diagnosis of a renal tumor (within past 3 months).
• • Measurable, predominantly (\> 80%) solid renal neoplasm between 1.5-5.0 cm.
• • Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic resonance imaging (MRI).
• • No definitive evidence of metastatic disease.
• • Does not require urgent surgical treatment.
• • Candidate for surgical, ablative, and surveillance approach.
• • Willingness to obtain more information to aid decision-making.
• • Understanding and willingness to provide consent.
• Exclusion Criteria:
• • Presence of multiple solid renal tumors.
• • A prior needle biopsy of the mass resulting in histologic diagnosis.
• • A prior diagnosis of kidney cancer.
• • Presence of an active, untreated, non-renal malignancy.
• • History of bleeding diathesis or recent bleeding episode.
• • Prior surgery or radiation therapy to the kidney.
• • Unwillingness to fill out questionnaires.